PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) today announced that KOMBIGLYZE ™ XR (saxagliptin and metformin HCl extended-release), ...
PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...
November 8, 2010 — The US Food and Drug Administration (FDA) has approved the first and only once-daily combination tablet featuring saxagliptin and extended-release (XR) metformin HCl (Kombiglyze XR; ...
Teva Pharmaceuticals USA, Inc. is voluntarily recalling fourteen (14) lots of Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg, 100 and 1000 count bottles, in the United States ...
Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...
Dr. Reddy’s Laboratories Ltd. on Thursday announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market. It is the generic version of KOMBIGLYZE XR ...
The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with ...
Three makers of Type 2 diabetes drug Metformin announced recalls Friday, the U.S. Food & Drug Administration reported. The reason for the voluntary recalls: the U.S. Food & Drug Administration ...
Canagliflozin and Metformin Hydrochloride Extended-Release Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Canagliflozin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback